People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Biotechnology, Pharmaceuticals, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Exagen Diagnostics Inc | — | Biotechnology | Series B | $88.5M | $261.4M | 2011 |
| GLO Pharma, Inc. | — | Pharmaceuticals | Series C | $60.4M | $1.2B | 2020 |
| Evida Biosciences Inc. | — | Biotechnology | Series C | $42.0M | $365.0M | 2024 |
| Planet Biopharmaceuticals, Inc. | — | Other Health Care | Seed | $1.5M | $37.2M | 2010 |
Scott Glenn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Scott Glenn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Lauren Otsuki | 2 | 4 |
| Michael Walsh | 1 | 24 |
| David Blivin | 1 | 14 |
| Dinesh Patel | 1 | 13 |
| Scott L. Glenn | 1 | 9 |
| Brian Birk | 1 | 8 |
| James L.L. Tullis | 1 | 6 |
| Brent Saunders | 1 | 5 |
| Andrew Schiff | 1 | 5 |
| Nicole Quinn | 1 | 4 |
| Waneta C. Tuttle | 1 | 4 |
| Robert Cole | 1 | 4 |
| Daniel C. Burrell | 1 | 3 |
| Lisa Davis | 1 | 3 |
| Shierley Widjaja | 1 | 3 |
| Todd Jackson | 1 | 2 |
| Michael J. Walsh | 1 | 2 |
| Rolf Benirschke | 1 | 2 |
| Michael R. Walsh | 1 | 2 |
| Brian G. Feagan, M.D. | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.